Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 473,800 shares, an increase of 136.2% from the September 30th total of 200,600 shares. Approximately 14.5% of the company’s shares are short sold. Based on an average daily volume of 368,100 shares, the days-to-cover ratio is currently 1.3 days.
Analyst Ratings Changes
Separately, Benchmark reissued a “buy” rating and set a $7.00 price target on shares of Biofrontera in a research note on Friday, August 16th.
Read Our Latest Stock Analysis on Biofrontera
Biofrontera Trading Down 6.4 %
Biofrontera (NASDAQ:BFRI – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($1.12) EPS for the quarter, beating the consensus estimate of ($1.19) by $0.07. The business had revenue of $7.84 million for the quarter, compared to analysts’ expectations of $9.02 million. Biofrontera had a negative net margin of 38.34% and a negative return on equity of 837.97%. Analysts predict that Biofrontera will post -3.11 EPS for the current fiscal year.
Biofrontera Company Profile
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
Further Reading
- Five stocks we like better than Biofrontera
- High Flyers: 3 Natural Gas Stocks for March 2022
- Texas Roadhouse Stock Steering for New Highs This Year
- 3 Fintech Stocks With Good 2021 Prospects
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Investing in Construction Stocks
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.